Skip to main content
. Author manuscript; available in PMC: 2009 Sep 18.
Published in final edited form as: Int J Cancer. 2009 Jun 1;124(11):2690–2696. doi: 10.1002/ijc.24256

Table VII.

XRCC1 polymorphisms, smoking, and association with site-specific head and neck squamous cell carcinoma, restricting to the HPV16 seronegative

≥20 Pack-
years		 XRCC1
variant
allele1 		Controls
n=491 (%)		 Laryngeal
Cases
n=75 (%)		 OR2 (95% CI) Oral Cavity
Cases
n=160 (%)		 OR2 (95% CI) Pharyngeal
Cases
n=103% (%)		 OR2 (95% CI)
No No 73 (14.9) 4 (5.3) referent 26 (16.2) referent 8 (7.8) referent
Yes 225 (45.8) 9 (12.0) 0.85 (0.25-2.89) 45 (28.1) 0.64 (0.35-1.16) 17 (16.5) 0.76 (0.31-1.86)
Yes No 64 (13.0) 19 (25.3) referent 21 (13.1) referent 19 (18.4) referent
Yes 129 (26.3) 43 (57.3) 1.08 (0.57-2.03) 68 (42.5) 1.56 (0.85-2.86) 59 (57.3) 1.51 (0.82-2.80)
P interaction 0.73 P interaction 0.04 P interaction 0.20
1

Had at least one variant allele in an XRCC1 polymorphism (194Trp, 280Gln, or 399Gln).

2

ORs estimated using a polytomous logistic model that controlled for age, sex, race, education, and alcohol consumption.